Antibody-drug conjugate · Cytotoxic, directed at delta-like protein 3 (DLL3) · developed by IDEAYA Biosciences
IDE849 is an antibody-drug conjugate made of a humanized IgG1 antibody that binds DLL3, a Notch pathway protein overexpressed on tumor cells, linked by a cleavable linker to a topoisomerase I inhibitor. After binding and internalization, the payload is released and inhibits DNA replication, causing tumor cell death. It is being studied in small-cell lung cancer, neuroendocrine carcinomas and other DLL3-expressing solid tumors.
Summary written with AI from the sources listed at the end of this page.
| Trial | Phase | Condition | Status | Sponsor |
|---|---|---|---|---|
| NCT07174583 | Phase 1/2 | Small-cell Lung Cancer | Recruiting | IDYA |
Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.
Neuroendocrine CarcinomasSmall-cell Lung CancerSolid Tumor Show to Express DLL3
See IDYA's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.
IDYA catalysts and pipeline →